ZAVESCA ® (miglustat) capsules An oral therapy for adults with mild to moderate type 1 Gaucher disease who cannot be treated with enzyme replacement therapy (ERT) 1 Reference: 1.

ZAVESCA ® is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 for whom ERT is not a therapeutic option (eg, …

The recommended dosage of ZAVESCA ® is usually 1 pill (100 mg) taken 3 times each day. 1 In some cases, your doctor may have you take less, due to side effects like tremors and …

Take ZAVESCA ® exactly as your healthcare provider tells you to. Take ZAVESCA ® at the same time each day. If you miss a dose of ZAVESCA ®, skip that dose. Take the next ZAVESCA ® …

ZAVESCA ® reduces the harmful buildup of glycosphingolipids throughout the body to help treat some of the symptoms of mild to moderate type 1 Gaucher disease.* 4 *Based on laboratory …

Select any of the links below to download information about type 1 Gaucher disease, ZAVESCA ® (miglustat) therapy, and healthy dietary choices that can help with this condition. Please …

New York prescribers, please submit prescription on an original NY State prescription blank. Federally approved, generic-equivalent medications will be dispensed for brand-name …

ZAVESCA ® Clinical Trials Study Design. ZAVESCA ® has been studied in approximately 80 patients with type 1 Gaucher disease across three clinical trials. The majority of patients were …

the management of the disease for which ZAVESCA is indicated. I have studied and familiarized myself with the ZAVESCA package insert, the safety and efficacy profile of ZAVESCA, and …

ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease